Recently, Shenzhen-Hong Kong Cell Valley (Shenzhen) Medical Technology Co., Ltd. received a letter of thanks from the Qianhai Shenzhen-Hong Kong Modern Service Industry Cooperation Zone Administration. The letter was signed by Comrade Wang Shourui, member of the Standing Committee of the Shenzhen Municipal Committee, Secretary and Director of the Qianhai Administration Bureau, fully affirming the series of achievements the company has achieved since its establishment in Qianhai in 2025, and placing high expectations for the company's future development.

The letter of thanks pointed out that under the strong leadership of the Shenzhen Municipal Party Committee and Municipal Government, Qianhai continues to deepen reform and opening up, focusing on the modern service industry and the main line of cooperation between Shenzhen and Hong Kong. Various core indicators have grown steadily, and development momentum has continued to increase. Against this background, Shenzhen-Hong Kong Cell Valley, as one of the representative cell and gene therapy (CGT) companies established in Qianhai, actively participates in the integration and development process of Qianhai’s biomedicine and modern service industries, and has achieved substantial breakthroughs in scientific research services, industrial collaboration and international cooperation.

The letter specifically mentions that the company continues to deepen its efforts in the field of cell and gene therapy, cooperates with many domestic and foreign scientific research and medical institutions, and promotes clinical research layout with more than 100 domestic tertiary hospitals; it has achieved phased results in obtaining DMF registration from the US FDA for NK immune cell-derived exosomes, which provides strong support for Qianhai to accelerate the layout of the cell and gene industry ecology.

In 2025, Shenzhen-Hong Kong Cell Valley will be officially launched in Qianhai. Focusing on the construction of a market-oriented public service platform for cell and gene therapy, it will actively connect policy resources and industrial elements, promote the transformation of scientific research results, cross-border collaboration and the docking of international standards, and gradually build an integrated service system of "research and development-preparation-compliance-clinical transformation-international expansion". The receipt of a letter signed by the main leaders of Qianhai Administration Bureau is not only an affirmation of the company's phased work, but also reflects Qianhai's great emphasis on the cell and gene therapy industry and its strategic layout determination.

Howard Shi, chairman of Cell Valley, said that he will continue to follow the overall deployment of the Shenzhen Municipal Party Committee, the Municipal Government and the Qianhai Administration Bureau, closely follow the national cell and gene therapy policy guidance, and rely on the cooperation advantages of Shenzhen and Hong Kong in Qianhai to accelerate the construction of an internationally competitive CGT one-stop service platform, strengthen technological innovation and compliance capacity building, deepen collaborative cooperation with Hong Kong and international medical research institutions, and promote more innovative results to be gathered in Qianhai, implemented in the Greater Bay Area, and radiated globally.

Facing 2026, Shenzhen-Hong Kong Cell Valley will promote platform construction and industrial upgrading to higher standards, help Qianhai build a cell and gene industry highland in the new journey of the "15th Five-Year Plan", and contribute to serving the innovative development of biomedicine in the Guangdong-Hong Kong-Macao Greater Bay Area and benefiting more patients and the health and welfare of the people.